The FDA approved Imdelltra more than three weeks ahead of its deadline, and based its decision on a trial showing the drug shrank tumors in 40% of patients who received it. Amgen will need to complete ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The US FDA has approved Amgen's Bkemv as an interchangeable biosimilar to Soliris for the treatment of specific rare diseases ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
Results from a mid-stage trial , opens new tab ... drugs. Amgen said it will need to complete its larger, pivotal trial in advanced small cell lung cancer to receive full FDA approval of the ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small ... antibody to gain FDA approval in cancer, and the first in small ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The Food and Drug ... made by Amgen to treat the most deadly form of lung cancer. The drug, called Imdelltra, can be used for patients with advanced small-cell lung cancer if another treatment ...
"The FDA's approval ... scientific officer at drug maker Amgen, said in a company news release. "Imdelltra offers these patients who are in urgent need of new innovative therapies hope ...